Table 2.
Demographic data, indication for cfLVAD-implantation and medical history of patients included in the derivation and the validation cohort. Values are expressed as numbers and % of patients, mean ± SD, or median [Interquartile Range]
| Derivation cohort 118 patients |
Validation cohort 72 patients |
|
|---|---|---|
| Demographic data | ||
| Age (years) | 49.4 ± 12.8 | 51.2 ± 13.0 |
| Male gender | 83 (70.3%) | 49 (68.1%) |
| Weight (kg) | 75.0 ± 14.0 | 75.6 ± 15.0 |
| Height (cm) | 177 ± 9 | 174 ± 23 |
| BSA (m2) | 1.92 ± 0.19 | 1.92 ± 0.22 |
| BMI (kg·m−2) | 23.9 ± 4.1 | 24.1 ± 3.8 |
| Indication LVAD implantation | ||
| Hypertrophic CMP | 3 (2.5%) | 1 (1.4%) |
| Ischemic CMP | 25 (21.2%) | 16 (22.2%) |
| Non-compaction CMP | 5 (4.2%) | 0 (0.0%) |
| Dilating CMP | 85 (72.0%) | 52 (72.2%) |
| Myocarditis | 0 (0.0%) | 1 (1.4%) |
| Congenital CMP | 0 (0.0%) | 1 (1.4%) |
| Toxic CMP | 0 (0.0%) | 1 (1.4%) |
| Medical History | ||
| Diabetes Mellitus | 9 (7.6%) | 10 (13.9%) |
| Hypertension | 10 (8.5%) | 10 (13.9%) |
| Hypercholesterolemia | 12 (10.2%) | 11 (15.3%) |
| Smoking history | 64 (54.2%) | 25 (34.7%) |
| Thyroid disease | 15 (12.7%) | 7 (9.7%) |
| COPD | 13 (11.0%) | 9 (12.5%) |
| Stroke | 7 (5.9%) | 4 (5.6%) |
| Transient Ischemic Attack | 6 (5.1%) | 3 (4.2%) |
| Previous Cardiothoracic surgery | 14 (11.9%) | 13 (18.1%) |
| HMIIRS | 2.4 ± 1.3 | 1.5 ± 1.0 |
| Euroscore II | 22.1 [17.3–34.0] | 19.0 [12.3–34.7] |
| Intermacs Class | ||
| Intermacs class I | 15 (12.7%) | 1 (1.4%) |
| Intermacs class II | 63 (53.4%) | 31 (43.1%) |
| Intermacs class III | 33 (28.0%) | 27 (37.5%) |
| Intermacs class IV | 7 (5.9%) | 12 (16.7%) |
| Intermacs class V | 0 (0.0%) | 0 (0.0%) |
| Intermacs class VI | 0 (0.0%) | 1 (1.4%) |